Almotriptan: a review of 10 years’ clinical experience

References

• Menken M, Munsat TL, Toole JF. The global burden of disease study: implications for neurology. Arch. Neurol.57, 418–420 (2000).
   PubMed Web of Science ®Google Scholar
• WHO. The Global Burden of Disease: 2004 Update. WHO, Geneva, Switzerland (2004).
   Google Scholar
• Goadsby PJ, Lipton RB, Ferrari MD. Migraine – current understanding and treatment. N. Engl. J. Med.346(4), 257–270 (2002).
   PubMed Web of Science ®Google Scholar
• Andlin-Sobocki P, Jönsson B, Wittchen HU, Olesen J. Cost of disorders of the brain in Europe. Eur. J. Neurol.12(Suppl. 1), 1–27 (2005).
   PubMed Web of Science ®Google Scholar
• Dodick DW. Acute and prophylactic management of migraine. Clin. Cornerstone4, 36–52 (2001).
   PubMedGoogle Scholar
• Evers S, Áfra J, Frese A et al. EFNS guideline on the drug treatment of migraine- revised report of an EFNS task force. Eur. J. Neurol.16(9), 968–981 (2009).
   PubMed Web of Science ®Google Scholar
• Ferrari MD, Roon KI, Lipton RB, Goadsby PJ. Oral triptans (serotonin 5-HT1B/1D agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet.358(9294), 1668–1675 (2001).
   PubMed Web of Science ®Google Scholar
• Ferrari MD, Goadsby PJ, Roon KI, Lipton RB. Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia22, 633–658 (2002).
   PubMed Web of Science ®Google Scholar
• Tepper SJ, Rapoport AM, Sheftell FD. Mechanisms of action of the 5-HT1B/1D receptor agonists. Arch. Neurol.59, 1084–1088 (2002).
   PubMed Web of Science ®Google Scholar
• McEwen J, Salva M, Jansat JM, Cabarrocas X. Pharmacokinetics and safety of oral almotriptan in healthy male volunteers. Biopharm. Drug Dispos.25(7), 303–311 (2004).
   PubMed Web of Science ®Google Scholar
• Garcia E, Cabarrocas X, Jansat JM. A clinical trial to determine the lack of food interaction on the bioavailability of Almotriptan, a new 5 HT1B/1D agonist, in healthy volunteers (Abstract). Headache38, 381 (1998).
   Google Scholar
• Gras J. Almotriptan, a new anti-migraine agent: a review. CNS Drug Rev.8, 217–234 (2002).
   PubMedGoogle Scholar
• Robert M, Warrington SJ, Zayas JM, Cabarrocas X, Fernández AG, Ferrer P. Electrocardiographic effects and pharmacokinetics of oral almotriptan in healthy subjects (Abstract). Cephalalgia18, 406 (1998).
   Google Scholar
• Cabarrocas X, Salvá M. Pharmacokinetic and metabolic data on almotriptan, a new antimigraine drug (Abstract). Cephalalgia17, 421 (1997).
   Google Scholar
• McEnroe JD, Fleishaker JC. Clinical pharmacokinetics of almotriptan, a serotonin 5-HT1B/1D receptor agonist for the treatment of migraine. Clin. Pharmacokinet.44, 237–246 (2005).
   PubMed Web of Science ®Google Scholar
• Salvá M, Palacios JM, Martinez-Tobed A. Metabolism of the novel anti-migraine compound almotriptan (LAS 31416) in humans. Presented at: The 6th International Society for the Study of Xenobiotics Meeting 30th June–3rd July 1997, Gothenberg, Sweden (Abstract).
   Google Scholar
• Cabarrocas X. Lack of pharmacokinetic interaction between almotriptan and oral contraceptives: a double-blind, placebo controlled, crossover study in healthy female volunteers (Abstract). Cephalalgia23, 716 (2003).
   Web of Science ®Google Scholar
• Cabarrocas X, Salvá M, Pavesi M, Costa J. Ethanol does not signficantly affect the bioavailability of almotriptan: an open, randomized, crossover, single-dose, Phase I clinical trial in healthy volunteers. Int. J. Clin. Pharmacol. Ther.44(9), 443–448 (2006).
   PubMed Web of Science ®Google Scholar
• Fleishaker JC, Sisson TA, Carel BJ, Azie NE. Pharmacokinetic interaction between verapamil and almotriptan in healthy volunteers. Clin. Pharmacol. Ther.67, 498–503 (2000).
   PubMed Web of Science ®Google Scholar
• Fleishaker JC, Ryan KK, Carel BJ, Azie NE. Evaluation of the potential pharmacokinetic interaction between almotriptan and fluoxetine in healthy volunteers. J. Clin. Pharmacol.41, 217–223 (2001).
   PubMed Web of Science ®Google Scholar
• Fleishaker JC, Sisson TA, Carel BJ, Azie NE. Lack of pharmacokinetic interaction between the antimigraine compound, almotriptan, and propranolol in healthy volunteers. Cephalalgia21, 61–65 (2001).
   PubMed Web of Science ®Google Scholar
• Fleishaker JC, Herman BD, Carel BJ, Azie NE. Interaction between ketoconazole and almotriptan in healthy volunteers. J. Clin. Pharmacol.43, 423–427 (2003).
   PubMed Web of Science ®Google Scholar
• Fleishaker JC, Ryan KK, Jansat JM et al. Effect of MAO-A inhibition on the pharmacokinetics of almotriptan, an antimigraine agent in humans. Br. J. Clin. Pharmacol.51(5), 437–441 (2001).
   PubMed Web of Science ®Google Scholar
• Palacios JM, Rabasseda X, Castañer J. Almotriptan. Drugs Fut.24, 367–374 (1999).
   Google Scholar
• Pascual J, Muñoz P. Correlation between lipophilicity and triptan outcomes. Headache45, 3–6 (2005).
   PubMed Web of Science ®Google Scholar
• Baldwin JR, Fleishaker JC, Azie NE, Carel BJ. A comparison of the pharmacokinetics and tolerability of the anti-migraine compound almotriptan in healthy adolescents and adults. Cephalalgia24, 288–292 (2004).
   PubMed Web of Science ®Google Scholar
• Cabarrocas X, Warrington SJ, Jansat JM. Pharmacokinetics and tolerability of oral almotriptan in the elderly (Abstract). Cephalalgia19, 363 (1999).
   Web of Science ®Google Scholar
• Tfelt-Hansen P, Block G, Dahlöf C et al. Guidelines for controlled trials of drugs in migraine: second edition. Cephalalgia20(9), 765–786 (2000).
   PubMed Web of Science ®Google Scholar
• Antonaci F, De Cillis I, Cuzzoni MG, Allena M. Almotriptan for the treatment of acute migraine: a review of early intervention trials. Expert Rev. Neurother.10(3), 351–364 (2010).
   PubMed Web of Science ®Google Scholar
• Dahlöf C, Tfelt-Hansen P, Massiou H, Fazekas A; Almotriptan Study Group. Dose finding, placebo-controlled study of oral almotriptan in the acute treatment of migraine. Neurology57(10), 1811–1817 (2001).
   PubMed Web of Science ®Google Scholar
• Dahlöf CG, Pascual J, Dodick DW, Dowson AJ. Efficacy, speed of action and tolerability of almotriptan in the acute treatment of migraine: pooled individual patient data from four randomized, double-blind, placebo-controlled clinical trials. Cephalalgia26(4), 400–408 (2006).
   PubMed Web of Science ®Google Scholar
• Pascual J, Falk RM, Piessens F et al. Consistent efficacy and tolerability of almotriptan in the acute treatment of multiple migraine attacks: results of a large randomized, double-blind placebo-controlled study. Cephalalgia20(6), 588–596 (2000).
   PubMed Web of Science ®Google Scholar
• Dowson AJ, Massiou H, Laínez JM, Cabarrocas X. Almotriptan is an effective and well-tolerated treatment for migraine pain: results of a randomized, double-blind, placebo-controlled clinical trial. Cephalalgia22(6), 453–461 (2002).
   PubMed Web of Science ®Google Scholar
• Spierings EL. Oral almotriptan vs. oral sumatriptan in the abortive treatment of migraine: a double-blind, randomized parallel group, optimum-dose comparison. Arch. Neurol.58(6), 944–950 (2001).
   PubMed Web of Science ®Google Scholar
• Lipton RB. What do patients with migraine want from acute migraine treatment? Headache42(Suppl. 1), 3–9 (2002).
   PubMed Web of Science ®Google Scholar
• Dahlöf CG. How does almotriptan compare with other triptans? A review of data from placebo-controlled clinical trials. Headache42(2), 99–113 (2002).
   PubMed Web of Science ®Google Scholar
• Pascual J, Falk R, Docekal R et al. Tolerability and efficacy of almotriptan in the long-term treatment of migraine. Eur. Neurol.45(4), 206–213 (2001).
   PubMed Web of Science ®Google Scholar
• Dodick DW, Sandrini G, Williams P. Use of the sustained pain-free plus no adverse events endpoint in clinical trials of triptans in acute migraine. CNS Drugs21(1), 73–82 (2007).
   PubMed Web of Science ®Google Scholar
• Láinez MJ, Galván J, Heras J, Vila C. Crossover, double-blind clinical trial comparing almotriptan and ergotamine plus caffeine for acute migraine therapy. Eur. J. Neurol.14(3), 269–275 (2007).
   PubMed Web of Science ®Google Scholar
• Cady RK, Lipton RB, Hall C, Stewart WF, O’Quinn S, Gutterman D. Treatment of mild headache in disabled migraine sufferers: results of the Spectrum Study. Headache40(10), 792–797 (2000).
   PubMed Web of Science ®Google Scholar
• Cady RK, Sheftell F, Lipton RB et al. Effect of early intervention with sumatriptan on migraine pain: retrospective analyses of data from three clinical trials. Clin. Ther.22(9), 1035–1048 (2000).
   PubMed Web of Science ®Google Scholar
• Ng-Mak DS, Cady R, Chen YT, Ma L, Bell CF, Hu XH. Can migraineurs accurately identify their headaches as ‘migraine’ at attack onset? Headache47(5), 645–653 (2007).
   PubMed Web of Science ®Google Scholar
• Linde M, Mellberg A, Dahlöf C. The natural course of migraine attacks. A prospective analysis of untreated attacks compared with attacks treated with a triptan. Cephalalgia26(6), 712–721 (2006).
   PubMed Web of Science ®Google Scholar
• Gendolla A. Early treatment in migraine: how strong is the current evidence? Cephalalgia28(Suppl. 2), 28–35 (2008).
   PubMedGoogle Scholar
• Tfelt-Hansen P, Saxena PR, Dahlöf C et al. Ergotamine in the acute treatment of migraine: a review and European consensus. Brain123, 9–18 (2000).
   PubMed Web of Science ®Google Scholar
• Burstein R, Yarnitsky D, Goor-Aryeh I, Ransil BJ, Bajwa ZH. An association between migraine and cutaneous allodynia. Ann. Neurol.47, 614–624 (2000).
   PubMed Web of Science ®Google Scholar
• Burstein R, Collins B, Jakubowski M. Defeating migraine pain with triptans: a race against the development of cutenous allodynia. Ann. Neurol.55(1), 19–26 (2004).
   PubMed Web of Science ®Google Scholar
• Mathew NT. A long-term, open-label study of oral almotriptan 12.5 mg for the treatment of acute migraine. Headache42(1), 32–40 (2002).
   Web of Science ®Google Scholar
• Pascual J, Cabarrocas X. Within-patient early versus delayed treatment of migraine attacks with almotriptan: the sooner the better. Headache42(1), 28–31 (2002).
   PubMed Web of Science ®Google Scholar
• Mathew NT. Early intervention with almotriptan improves sustained pain-free response in acute migraine. Headache43(10), 1075–1079 (2003).
   PubMed Web of Science ®Google Scholar
• Dowson AJ, Massiou H, Laínez JM, Cabarrocas X. Almotriptan improves response rates when treatment is within 1 hour of migraine onset. Headache44(4), 318–322 (2004).
   PubMed Web of Science ®Google Scholar
• Pascual J, Láinez JM, Leira R, Titus F, Mateos V, Galván J; Grupo de Estudio TEA 2000. Almotriptan in the treatment of migraine attacks in clinical practice: results of the TEA 2000 observational study. Neurologia18(1), 7–17 (2003).
   PubMed Web of Science ®Google Scholar
• Tranche Iparraguirre S, Martínez Eizaguirre JM, Galván Cervera J; Grupo de Estudio TEA 2001. Tolerance to almotriptan and its effectiveness in primary care. Aten. Primaria35, 52–53 (2005).
   PubMedGoogle Scholar
• Láinez MJ. Clinical benefits of early triptan therapy for migraine. Cephalalgia24(Suppl. 2), 24–30 (2004).
   PubMed Web of Science ®Google Scholar
• Lantéri-Minet M, Allaf B, Mick G. Right triptan use in clinical conditions: results of the TEMPO study. Neurology66, 43 (2006).
   Google Scholar
• Freitag FG, Finlayson G, Rapoport AM et al. Effect of pain intensity and time to administration on responsiveness to almotriptan: results from AXERT 12.5 mg Time Versus Intensity Migraine Study (AIMS). Headache47(10), 519–530 (2007).
   PubMed Web of Science ®Google Scholar
• Mathew NT, Finlayson G, Smith TR et al. Early intervention with almotriptan: results of the AEGIS trial (AXERT® Early Migraine Intervention Study). Headache.47(2), 189–198 (2007).
   PubMed Web of Science ®Google Scholar
• Freitag FG, Smith T, Mathew N et al. Effect of early intervention with almotriptan vs placebo on migraine-associated functional disability: results from the AEGIS Trial. Headache48, 341–354 (2008).
   PubMed Web of Science ®Google Scholar
• Goadsby PJ, Zanchin G, Geraud G et al. Early vs. non-early intervention in acute migraine-‘Act when Mild (AwM)’. A double-blind, placebo-controlled trial of almotriptan. Cephalalgia28, 383–391 (2008).
   PubMed Web of Science ®Google Scholar
• Goadsby PJ. The ‘Act when mild’ (AwM) study: a step forward in our understanding of early treatment in acute migraine. Cephalalgia28(Suppl. 2), 36–41 (2008).
   PubMed Web of Science ®Google Scholar
• Lucas C, Géraud G, Valade D, Chautard MH, Lantéri-Minet M. Recognition and therapeutic management of migraine in 2004, in France: results of FRAMIG 3, a French nationwide population-based survey. Headache46(5), 715–725 (2006).
   PubMed Web of Science ®Google Scholar
• Shapero G, Dowson A, Lacoste JP, Almqvist P. Improved migraine management in primary care: results of a patient treatment experience study using zolmitriptan orally disintegrating tablet. Int. J. Clin. Pract.60(12), 1530–1535 (2006).
   PubMed Web of Science ®Google Scholar
• Lantéri-Minet M, Diaz-Insa S, Leone M, Vila C, Clissold SP. Efficacy of almotriptan in early intervention for treatment of acute migraine in a primary care setting: the START study. Int. J. Clin. Pract.64(7), 936–943 (2010).
   PubMed Web of Science ®Google Scholar
• Charles JA. Almotriptan in the acute treatment of migraine in patients 11–17 years old: an open-label pilot study of efficacy and safety. J. Headache Pain7, 95–97 (2006).
   PubMedGoogle Scholar
• Linder SL, Mathew NT, Cady RK, Finlayson G, Ishkanian G, Lewis DW. Efficacy and tolerability of almotriptan in adolescents: a randomized, double-blind, placebo-controlled trial. Headache48(9), 1326–1336 (2008).
   PubMed Web of Science ®Google Scholar
• Allais G, Acuto G, Cabarrocas X, Esbri R, Benedetto C, Bussone G. Efficacy and tolerability of almotriptan versus zolmitriptan for the acute treatment of menstrual migraine. Neurol. Sci.27, 193–197 (2006).
   PubMed Web of Science ®Google Scholar
• Diamond ML, Cady RK, Mao L et al. Characteristics of migraine attacks and responses to almotriptan treatment: a comparison of menstrually related and nonmenstrually related migraines. Headache48(2), 248–258 (2008).
   PubMed Web of Science ®Google Scholar
• Allais G, D’Andrea G, Moschiano F. A randomized, prospective, cross-over, double-blind, placebo-controlled multicentre study to assess the efficacy and tolerability of almotriptan 12.5 mg in menstrually-related migraine (Abstract P005). Cephalalgia29, 1–166 (2009).
   Google Scholar
• Silberstein SD. Migraine. Lancet.363(9406), 381–391 (2004).
   PubMed Web of Science ®Google Scholar
• Schoenen J, De Klippel N, Giurgea S et al. Almotriptan and its combination with aceclofenac for migraine attacks: a study of efficacy and the influence of auto-evaluated brush allodynia. Cephalalgia28(10), 1095–1105 (2007).
   Web of Science ®Google Scholar
• Pascual J, Diener HC. Use of almotriptan in triptan-experienced and triptan-naive patients. Curr. Med. Res. Opin.23(10), 2433–2440 (2007).
   PubMed Web of Science ®Google Scholar
• Dahlöf CG. Infrequent or non-response to oral sumatriptan does not predict response to other triptans – review of four trials. Cephalalgia26(2), 98–106 (2006).
   PubMed Web of Science ®Google Scholar
• Diener HC, Gendolla A, Gebert I, Beneke M. Almotriptan in migraine patients who respond poorly to oral sumatriptan: a double-blind, randomized trial. Headache.45(7), 874–882 (2005).
   PubMed Web of Science ®Google Scholar
• Stark S, Spierings EL, McNeal S, Putnam GP, Bolden-Watson CP, O’Quinn S. Naratriptan efficacy in migraineurs who respond poorly to oral sumatriptan. Headache40, 513–520 (2000).
   PubMed Web of Science ®Google Scholar
• Gallagher RM, Kunkel R. Migraine medication attributes important for patient compliance: concerns about side effects may delay treatment. Headache43(1), 36–43 (2003).
   PubMed Web of Science ®Google Scholar
• Dodick DW. Oral almotriptan in the treatment of migraine: safety and tolerability. Headache.41(5), 449–455 (2001).
   PubMed Web of Science ®Google Scholar
• Boyce M, Dunn K, Warrington S. Hemodynamic and electrocardiographic effects of almotriptan in healthy volunteers. J. Cardiovasc. Pharmacol.37(3), 280–289 (2001).
   PubMedGoogle Scholar
• Houghton LA, Foster JM, Whorwell PJ, Morris J, Fowler P. Is chest pain after sumatriptan oesophageal in origin? Lancet314(8928), 985–986 (1994).
   Google Scholar
• Dodick DW. Triptans and chest symptoms: the role of pulmonary vasoconstriction. Cephalalgia.24(4), 298–304 (2004).
   PubMedGoogle Scholar
• Dodick DW, Martin VT, Smith T, Silberstein S. Cardiovascular tolerability and safety of triptans: a review of clinical data. Headache44(Suppl. 1), S20–S30 (2004).
   PubMedGoogle Scholar
• Janknegt R. Triptans in the treatment of migraine: drug selection by means of the SOJA method. Expert Opin. Pharmacother.8(Suppl. 1), S15–S30 (2007).
   PubMed Web of Science ®Google Scholar
• Dodick DW. Applying the benefits of the AwM study in the clinic. Cephalalgia.28(Suppl. 2), 42–49 (2008).
   PubMed Web of Science ®Google Scholar
• Dodick DW. A review of the clinical efficacy and tolerability of almotriptan in acute migraine. Expert Opin. Pharmacother.4(7), 1157–1163 (2003).
   PubMed Web of Science ®Google Scholar
• De Klippel N, Jansen JP, Carlos JS. Survey to evaluate diagnosis and management of headache in primary care: Headache Management Pattern programme. Curr. Med. Res. Opin.24(12), 3413–3422 (2008).
   PubMedGoogle Scholar
• Sculpher M, Millson D, Meddis D, Poole L. Cost–effectiveness analysis of stratified versus stepped care strategies for acute treatment of migraine: The Disability in Strategies for Care (DISC) Study. Pharmacoeconomics20(2), 91–100 (2002).
   PubMed Web of Science ®Google Scholar
• Géraud G, Lánteri-Minet M, Lucas C Valade D; French Society for the Study of Migraine Headache (SFEMC). French guidelines for the diagnosis and management of migraine in adults and children. Clin. Ther.26(8), 1305–1318 (2004).
   PubMed Web of Science ®Google Scholar
• Edmeads J. Understanding the needs of migraine patients. Drugs66(Suppl.), 1–8 (2006).
   Web of Science ®Google Scholar
• Foley KA, Cady R, Martin V et al. Treating early versus treating mild: timing of migraine prescription medications among patients with diagnosed migraine. Headache45(5), 538–545 (2005).
   PubMed Web of Science ®Google Scholar
• Craven A, Shannon K. World Headache Alliance: raising headache awareness worldwide. J. Headache Pain4(Suppl.), 77–79 (2003).
   Google Scholar
• International Headache Society. The International Classification of Headache Disorders (Second Edition). Blackwell Publishing, Oxford, UK (2005).
   Google Scholar